Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + pegylated liposomal doxorubicin + hyperthermia
- Development stage
- Phase 2
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Fluorouracil + pegylated liposomal doxorubicin + hyperthermia is a combination therapy regimen investigated by The University of Texas Health Science Center, Houston, for the treatment of advanced gynecological and breast malignancies. The regimen consists of the antimetabolite fluorouracil (5-FU), which inhibits thymidylate synthase to disrupt DNA synthesis, and pegylated liposomal doxorubicin, an anthracycline that intercalates DNA and inhibits topoisomerase II. These chemotherapeutic agents are administered in conjunction with mild whole-body hyperthermia (WBH), a procedure that raises the body temperature to approximately 39.5-41.0°C. The rationale for adding hyperthermia is to increase blood flow and vascular permeability within the tumor microenvironment, thereby enhancing the delivery and cytotoxic efficacy of the liposomal and small-molecule drugs. This approach has been evaluated in Phase I/II clinical trials for patients with metastatic breast, ovarian, endometrial, and cervical cancers.
- Other names
- 5-fluorouracil + pegylated liposomal doxorubicin + whole-body hyperthermia5-FU + PLD + WBH
02
Targets
DNATOP2A (DNA topoisomerase II)TS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + pegylated liposomal doxorubicin + hyperthermia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + pegylated liposomal doxorubicin + hyperthermia.